Skip to the page

Data / Crowdfunding / New Jersey / Throne Biotechnologies Inc.

Throne Biotechnologies Inc.: crowdfunding raise on StartEngine Capital, LLC, $9,996 to $1,006,995 (2022)

Throne Biotechnologies Inc., a corporation in Paramus, NJ, filed a Form C with the SEC on February 25, 2022 to raise $9,996 to $1,006,995 in common stock through StartEngine Capital, LLC. The offering closed on April 30, 2022. In its most recent fiscal year it reported $0 in revenue and a net loss of $482,168, with 5 employees.

SpecStream is the live web data engine for teams and agents. It reads every Form C on SEC EDGAR each morning, and this page is that reading. Ask for your own cut (a portal, a state, a size, a revenue range) and new raises arrive in your sheet, CRM, Slack or agent as they land.

Website
thronebio.com
Funding portal
StartEngine Capital, LLC
Address
10 Forest Avenue, Suite 110, Paramus, NJ 07652
Legal form
Corporation
Jurisdiction
DE
Incorporated
January 19, 2011
SEC CIK
0001912674

Offering terms

From the offering filed February 25, 2022.

Security
Common Stock
Price
$7.59
Target
$9,996
Maximum
$1,006,995
Deadline
April 30, 2022
Portal compensation
7 - 13 percent

Financials

From the Form C filed February 25, 2022.

Most recent fiscal yearPrior fiscal yearSource
Revenue$0$0sec.gov
Cost of goods sold$0$0sec.gov
Net income$-482,168$-496,520sec.gov
Taxes paid$0$0sec.gov
Total assets$2,201,526$2,619,727sec.gov
Cash$59,519$208,101sec.gov
Accounts receivable$0$0sec.gov
Short-term debt$360,000$360,000sec.gov
Long-term debt$409,055$383,699sec.gov

Filings

FiledFilingTargetMaximumDeadlineNoteSource
February 25, 2022Offering$9,996$1,006,995April 30, 2022sec.gov

All filings on sec.gov

Updated February 25, 2022. Read from SEC EDGAR. Public domain (U.S. government work). Financials are as each company reported them in its Form C, unaudited unless the filing says otherwise. Websites are the ones the companies declared to the SEC. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.